Publications

Recent Papers in press/published:

Yu J, Mitsui T, Wei M, Mao H, Butcher J, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM Jr, Loughran TP Jr, Tridandapani S, Caligiuri MA.  NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and man.  J Clin Invest, 2011 in press

Vivier E, Raulet DH, Moreetta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells.  Science 331:44-9, 2011


Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A. Immature NK Cells, Capable of Producing IL-22, Are Present in Human Uterine Mucosa. J Immunol. 2010 Oct 1;185(7):3913-3918. Epub 2010 Aug 27.

Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci  G, Bloomfield CD. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Jul 23. [Epub ahead of print] PubMed PMID: 20656931.

Hughes T, Becknell B, Freud AG, McClory S, Briercheck E, Yu J, Mao C, Giovenzana C, Nuovo G, Wei L, Zhang X, Gavrilin MA, Wewers MD, Caligiuri MA.Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity. 2010 Jun 25;32(6):803-14.PMID: 20620944 [PubMed - indexed for MEDLINE]

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 May 4. [Epub ahead of print] PubMed PMID: 20442368.

Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. The PD-1 / PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1 antibody. Blood. 2010 May 11.

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010 Apr 13; 17(4):333-47. PubMed PMID: 20385359.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 May 10; 28(14):2348-55. Epub 2010 Apr 5. PubMed PMID: 20368543.

Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA. In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. J Immunol. 2010 Mar 15;184(6):2769-75. Epub 2010 Feb 8


Freud AG, Caligiuri MA. Purification of human NK cell developmental intermediates from lymph nodes and tonsils. Methods Mol Biol. 2010;612:1-14.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010 Feb 1; 28(4):596-604. Epub 2009 Dec 21. PubMed PMID: 20026798; PubMed Central PMCID: PMC2815994.

Yu J, Mao H, Wei M, Hughes T, Zhang J, Park IK,  Liu S, McClory S, Marcucci G, Trotta R, Caligiuri MA. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets. Blood.  115:274-81, 2010 Jan 14.

Yokohama A,* Mishra A,* Mitsui T, Becknell B, Johns J, Curphey D, Blaser BW, Vandeusen JB, Mao H, Yu J, Caligiuri MA. A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia. Leuk Res. 2010 Feb; 34(2):203-9. Epub 2009 Aug 5.

Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman  SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009 Jul 1; 27(19):3198-204. Epub 2009 May 18. PubMed PMID: 19451432; PubMed Central PMCID: PMC2716941.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, Roda JM, Cheney C, Mo X, Lehman, A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N, Byrd JC. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain engineered monoclonal antibody. Blood.  115:1204-13, 2010 Feb 11

Park IK, Giovenzana C., Hughes T.L., Yu J., Trotta R., and Caligiuri M.A. The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development. Blood. 113:2470-7, 2009 Mar 12.

Benson D.M. Jr, Yu J., Becknell B., Wei M., Freud A.G., Ferketich AK., Trotta R., Perrotti D., Briesewitz R., and Caligiuri M.A. Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells. Blood. 113:2706-14, 2009 Mar 19.

Yu J., Ershler M., Yu L., Wei M., Hackanson B., Yokohama A., Mitsui T., Liu C., Mao H., Liu S., Liu Z., Trotta R., Liu C.G., Liu X., Huang K., Visser J., Marcucci G., Plass C., Belyavsky A.V., Caligiuri M.A..  TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood 113:5558-67, 2009

Hughes T, Becknell B, McClory S, Briercheck E, Freud AG, Zhang X, Mao H, Nuovo G, Yu J, Caligiuri MA. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood. 2009 Apr 23;113(17):4008-10. Epub 2009 Feb 24

Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park IK, Hwang C, Liu S, Trotta R, Benson Jr DM, Caligiuri MA CD94 defines phenotypically and  functionally distinct mouse NK cell subsets. J. Immunology. 183:4968-74, 2009

Costinean S, Sandhu SK., Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR,  Shidham A, Croce CM. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by Mir-155 in B cells of Emicro-MIR-155 transgenic mice. Blood 114:1374-1382, 2009

Park IK, Giovenzana C, Hughes TL, Yu J, Trotta R, and Caligiuri MA.  The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.  Blood. 2009 113, 2470-2477.

Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP.  The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood, 112(6):2508-11, 2008.  

Published Abstract/Presentations

Bernot KM, Zorko NA, Liu S, Santhanam R, Whitman SP, Dorrance AM, Chen K, Zou X, Mao C, Wen J, Kalu C, Jamieson R, Lee BH, Gilliland DG, Marcucci G, and Caligiuri MA. Personalized Medicine in Acute Myeloid Leukemia:  Targeting Epigenetics and Tyrosine Kinases in a Transplant Mouse Model of MLL-PTD; FLT3-ITD Leukemia. Poster Presented at: The Ohio State University Medical Center Research Day; April 8, 2010; Columbus, OH

*Bernot KM, Zorko NA, Liu S, Santhanam R, Whitman SP, Dorrance AM, Chen K, Zou X, Mao C, Wen J, Kalu C, Jamieson R, Lee BH, Gilliland DG, Marcucci G, and Caligiuri MA. Personalized Medicine in Acute Myeloid Leukemia:  Targeting Epigenetics and Tyrosine Kinases in a Transplant Mouse Model of MLL-PTD; FLT3-ITD Leukemia. Poster Presented at: The Ohio State University Comprehensive Cancer Center 12th Annual Scientific Meeting Targeted Cancer Therapies: Discovery to Personalized Medicine; February 19, 2010; Columbus, OH
 *recipient of Postdoctoral travel award for poster presentation

Ciarlariello D, Trotta R, Mao H, Yu J, Dal Col J, and Caligiuri M. The PP2A inhibitor SET regulates cytotoxicity and Granzyme B expression in human NK cells.  The Ohio State University Comprehensive Cancer Center 12th Annual Scientific Meeting Targeted Cancer Therapies: Discovery to Personalized Medicine; February 19, 2010; Columbus, OH

Mishra A, Liu S, Curphey DP, Sams GH, Sullivan LA, Zou X, Johns, J James K, Wang D, Kulp SK, Chen CS, LaPerla K, Wong H, Porcu PG, Garzon R, Marcucci G, Caligiuri MA. A novel mouse model of Cutaneous T-Cell Lymphoma Poster presentation at The Ohio State University Comprehensive Cancer Center 12th Annual Scientific Meeting Targeted Cancer Therapies: Discovery to Personalized Medicine; February 19, 2010; Columbus, OH

Mishra A, Liu S, Curphey DP, Sams GH,  Zou X, Pang, J Ramasamy S, Caserta E, Yang X, Wu LC, James KA, Becker H, Wu YZ, Metzeler, KH, Chan KK, LaPerla K, Garzon R, Lee RJ, Marcucci G, Caligiuri MA. Interleukin (IL)-15 and miR-29b leukemogeneic interplay: a novel therapeutic target for large granular lymphocytic leukemia.  The Ohio State University Comprehensive Cancer Center 12th Annual Scientific Meeting Targeted Cancer Therapies: Discovery to Personalized Medicine; February 19, 2010; Columbus, OH

Park IK, Mishra A, Chandler J, Briesewitz R, Caligiuri MA. Inhibition of FLT3 by blocking the Axl/Gas6 pathway in acute myeloid leukemia. The Ohio State University Comprehensive Cancer Center 12th Annual Scientific Meeting Targeted Cancer Therapies: Discovery to Personalized Medicine; February 19, 2010; Columbus, OH

Schwind S, Marcucci G, Maharry, K, Mrozek K, Radmacher MD, Holland KB, Becker H, Whitman SP, Wu YU, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield Aberrant Gene Expression of BAALC and ERG in Older [60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study. Blood (ASH Annual Meeting Abstracts) 114: 214.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Whitman SP, Paschka P, Margeson D, Wu YZ, Schwind S, Langer C, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson  RA, Bloomfield CD. Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study. Blood (ASH Annual Meeting Abstracts) 114: 326.

Whitman SP, Maharry K, Radmacher MD, Mrozek K, Margeson D, Holland KD, Becker H, Wu YZ, Schwind D, Baer MR, Powell BL, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study. Blood (ASH Annual Meeting Abstracts) 114: 1579.

Attar EC, Maharry K, Mrozek K, Radmacher MD, Whitman SP, Paschka P, Langer C, Holland KB, Powell BL, Kolitz JE, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study. Blood (ASH Annual Meeting Abstracts) 114: 1616.

Marcucci G, Maharry K, Whitman SP, Paschka P, Baldus CD, Langer C, Mrozek K, Kolitz JE, Larson RA, Bloomfield CD. Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts).  A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 27:15s, 2009 (suppl; abstr 7002)

Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman Sp, Paschka P, Mrozek, K, Kolitz JE, Larson Ra, Bloomfield CD. MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML). A Cancer and Leukemia Group B (CALGB) study. J Clin Oncol 27:15s, 2009 (suppl; abstr 7001)

Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman Sp, Mrozek K, Baer MR, Larson RA, Bloomfield CD. NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML). Clin Oncol 27:15s, 2009 (suppl; abstr 7000)

Awan FT, Lapalombella R., Trotta R., Butchar JP, Yu B, Benson DM Jr, Cheney C., Mo X., Lehman, A., Jones J., Flynn J., Jarjoura D., Baiocchi R.A., Desjarlais JR, Tridandapani S., Caligiuri MA, Muthusamy N., Byrd JC. CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody. 51st  Annual Meeting American Society of Hematology, Dec 5-8, 2009. New Orleans LA

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey C, Yu Jianhua, Mishra A, Becker H, Chenglong L, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, Marcucci

G. Evidence of MicroRNA-29b and Sp-1/ NF{kappa}B-HDAC Regulatory Network for KIT expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and therapeutic implications.  Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 938.

 

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu